CEL-SCI Corporation
$3.94
▲
1.17%
2026-04-21 06:19:00
cel-sci.com
ASE: CVM
Explore CEL-SCI Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$33.32 M
Current Price
$3.94
52W High / Low
$13.48 / $1.98
Stock P/E
—
Book Value
$1.38
Dividend Yield
—
ROCE
-107.75%
ROE
-2.12%
Face Value
—
EPS
$-3.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1
Debt / Equity
81.75
Current Ratio
1.4
Quick Ratio
2.2
Forward P/E
-4.42
Price / Sales
—
Enterprise Value
$35.76 M
EV / EBITDA
-1.68
EV / Revenue
—
Rating
None
Target Price
$25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 2. | aTyr Pharma, Inc. | $0.85 | — | $83.68 M | — | -99.71% | -1.08% | $7.29 / $0.64 | $0.69 |
| 3. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 4. | TG Therapeutics, Inc. | $36.96 | 12.6 | $5.64 B | — | 13.56% | 1.03% | $46.48 / $25.28 | $4.52 |
| 5. | Pyxis Oncology, Inc. | $1.7 | — | $104.3 M | — | -119.93% | -91.44% | $5.55 / $0.89 | $0.85 |
| 6. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 7. | Upstream Bio, Inc. | $9.99 | — | $543.66 M | — | -47.12% | -35.44% | $33.68 / $7.25 | $6.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.37 M | -6.03 M | -5.49 M | -6.39 M | -6.89 M | — |
| Net Profit | -5.47 M | -6.1 M | -5.66 M | -6.57 M | -7.07 M | — |
| EPS in Rs | -0.65 | -0.72 | -0.67 | -0.78 | -0.84 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -24.81 M | -26.35 M | -31.48 M | -36.06 M |
| Net Profit | -25.41 M | -26.92 M | -32.19 M | -36.7 M |
| EPS in Rs | -3 | -3.18 | -3.81 | -4.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 28.16 M | 26.99 M | 30.53 M | 50.52 M |
| Total Liabilities | 12.2 M | 14.12 M | 17.31 M | 18.36 M |
| Equity | 15.96 M | 12.87 M | 13.21 M | 32.16 M |
| Current Assets | 11.6 M | 6.06 M | 6.92 M | 25.44 M |
| Current Liabilities | 5.13 M | 4.62 M | 5.59 M | 4.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -17.12 M | -18.81 M | -22.85 M | -18.24 M |
| Investing CF | -0.04 M | -0.11 M | -0.37 M | 5.49 M |
| Financing CF | 23.37 M | 19.51 M | 4.69 M | -0.64 M |
| Free CF | -17.16 M | -18.92 M | -23.22 M | -18.9 M |
| Capex | -0.04 M | -0.11 M | -0.37 M | -0.66 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 16.38% | 12.28% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-05-20 | 1:0.0333333 |